HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiarelli, F. Articles by Verrotti, A. Search for Related Content PubMed PubMed Citation Articles by Chiarelli, F. Articles by Verrotti, A. Social Bookmarking                What's this?

Effects of Irbesartan on Intracellular Antioxidant Enzyme Expression and Activity in Adolescents and Young Adults With Early Diabetic Angiopathy

¹ Department of Pediatrics, University of Chieti, Chieti, Italy
² Department of Medicine, University of Chieti, Chieti, Italy

Address correspondence and reprint requests to Francesco Chiarelli, Department of Pediatrics, University of Chieti, Ospedale Policlinico, Via dei Vestini, 5, I-66100 Chieti, Italy. E-mail: chiarelli{at}unich.it

OBJECTIVE—Defective intracellular antioxidant enzyme production (IAP) has been demonstrated in adults with diabetic nephropathy. The objective of this study was to evaluate the effects of irbesartan, an angiotensin II receptor antagonist, on IAP in adolescents and young adults with type 1 diabetes and early signs of retinopathy and nephropathy.

RESEARCH DESIGN AND METHODS—This prospective, matched case-control study was conducted between November 2001 and December 2002 among 14 type 1 diabetic patients with early signs of angiopathy (ages 14–21 years), 11 type 1 diabetic patients without angiopathy (ages 12–22 years), and 10 healthy volunteers (ages 16–22 years). Skin fibroblasts were obtained by skin biopsies from the anterior part of the forearm and cultured in Dulbecco’s modified Eagle’s medium. The activity and mRNA expression of CuZn superoxide dismutase (CuZnSOD), Mn superoxide dismutase (MnSOD), catalase (CAT), and glutathione peroxidase (GPX) were measured before and after 6 months of treatment with irbesartan (150 mg/day); on both occasions, antioxidant enzyme activity was evaluated at different glucose concentrations (5 and 22 mmol/l).

RESULTS—At a normal glucose concentration (5 mmol/l), the activity and mRNA expression of CuZnSOD (0.50 ± 0.21 units/mg protein, 4.4 ± 1.5 mRNA/glyceraldehyde-3-phosphate dehydrogenase), MnSOD (0.26 ± 0.04 units/mg protein, 0.08 ± 0.07 mRNA), CAT (0.32 ± 0.08 units/mg protein, 4.8 ± 1.3 mRNA), and GPX (0.53 ± 0.09 units/mg protein, 2.2 ± 0.9 mRNA) were not different among the three groups (only values of diabetic subjects with angiopathy are shown). At high glucose concentrations, the activity and mRNA expression of CuZnSOD increased similarly in all groups (diabetic subjects with angiopathy: 0.93 ± 0.26 units/mg protein, 9.4 ± 2.1 mRNA); that of CAT and GPX increased in only control subjects and diabetic subjects without angiopathy (diabetic subjects with angiopathy: 0.33 ± 0.09 units/mg protein and 5.0 ± 1.4 mRNA; 0.54 ± 0.10 units/mg protein and 2.3 ± 1.0 mRNA, respectively). MnSOD did not change in any group. Treatment with irbesartan in adolescents with diabetic angiopathy was able to restore CAT and GPX activity and mRNA expression after exposure to high glucose concentrations. Markers of oxidative stress (serum malondialdehyde, fluorescent products of lipid peroxidation, monocyte chemoattractant protein-1, and 8-isoprostanes prostaglandin F₂) were significantly reduced after treatment with irbesartan.

CONCLUSIONS—Adolescents and young adults with early signs of diabetic angiopathy have defective intracellular antioxidant enzyme production and activity. Treatment with irbesartan can substantially improve the activity and production of these enzymes in skin fibroblasts.

Abbreviations: AER, albumin excretion rate • ANG-II, angiotensin II • CAT, catalase • CuZnSOD, CuZn superoxide dismutase • DMEM, Dulbecco’s modified Eagle’s medium • GAPDH, glyceraldehyde-3-phosphate dehydrogenase • GPX, glutathione peroxidase • MCP-1, monocyte chemoattractant protein 1 • MnSOD, Mn superoxide dismutase • PGF_2a, prostaglandin F_2a • RAS, renin-angiotensin system • SOD, superoxide dismutase • SSC, standard sodium citrate

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. Guo, Z. Xia, J. Jiang, and J. H. McNeill Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1728 - H1736. [Abstract] [Full Text] [PDF]

				M. L. Caramori, Y. Kim, P. Fioretto, C. Huang, S. S. Rich, M. E. Miller, G. B. Russell, and M. Mauer Cellular basis of diabetic nephropathy: IV Antioxidant enzyme mRNA expression levels in skin fibroblasts of type 1 diabetic sibling pairs Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3122 - 3126. [Abstract] [Full Text] [PDF]

				C. Huang, Y. Kim, M. L. Caramori, J. H. Moore, S. S. Rich, J. C. Mychaleckyj, P. C. Walker, and M. Mauer Diabetic Nephropathy Is Associated With Gene Expression Levels of Oxidative Phosphorylation and Related Pathways Diabetes, June 1, 2006; 55(6): 1826 - 1831. [Abstract] [Full Text] [PDF]